Immunotherapy of Nivolumab with Dendritic Cell Vaccination Is Effective against Intractable Recurrent Primary Central Nervous System Lymphoma: A Case Report
Author:
Affiliation:
1. Department of Neurosurgery, Osaka Medical College
2. Department of Neurosurgery, Kitano Hospital, Tazuke Kofukai Medical Research Institute
3. Saisei Mirai Medical Corporation
4. Department of Pathology, Osaka Medical College
Publisher
Japan Neurosurgical Society
Subject
Neurology (clinical),Surgery
Link
https://www.jstage.jst.go.jp/article/nmc/57/4/57_cr.2016-0330/_pdf
Reference26 articles.
1. 1) Glass J, Gruber ML, Cher L, Hochberg FH: Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: Long-term outcome. J Neurosurg 81: 188–195, 1994
2. 2) Hiraga S, Arita N, Ohnishi T, Kohmura E, Yamamoto K, Oku Y, Taki T, Sato M, Aozasa K, Yoshimine T: Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 91: 221–230, 1999
3. 3) Reni M, Ferreri AJ, Villa E: Second-line treatment for primary central nervous system lymphoma. Br J Cancer 79: 530–534, 1999
4. 4) Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbe C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA: Nivolumab in previously untreated melanoma without braf mutation. New Engl J Med 372: 320–330, 2015
5. 5) Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Jr., Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-ctla-4 treatment (checkmate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16: 375–384, 2015
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors;Antibodies;2023-04-04
2. Is CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma?;Frontiers in Oncology;2023-01-05
3. A Case of Lymphomatosis Cerebri Presenting with Rapid Progression of Dementia: A Literature Review;NMC Case Report Journal;2022-12-31
4. Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma;Hematology;2022-01-24
5. Targeting Bruton's tyrosine kinase in primary central nervous system lymphoma;Current Opinion in Neurology;2021-09-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3